|
|
Post by uvula on Aug 14, 2014 8:42:22 GMT -5
It seems like the company is still being quiet. Could this mean another deal is in the works. Could be good. Could be bad.
|
|
|
|
Post by cybergym66 on Aug 14, 2014 9:03:24 GMT -5
It seems like the company is still being quiet. Could this mean another deal is in the works. Could be good. Could be bad. I don't think so...I just think MNKD is not very good at the PR needed now that the partnership is announced. You can see the effect of a lack of it by how the stock price continues to get pushed down since there's no positive news from them. The partnership announcement didn't really have clear marketing or sales projections and from just reading this board, it seems a lot of questions still need to be answered. I'm sure this is also the reason hedge funds aren't aggressively buying the stock (they might be nibbling, but no BIG buys). |
|
|
|
Post by kc on Aug 14, 2014 16:34:35 GMT -5
I disagree. Something is on the horizon. Going back to FDA approval. They knew the deal coming with Sanofi and did their best to keep it under wraps. Management could have hit TV and other media for weeks talking about the significance of getting FDA approval. Such a big milestone. What did we get SILENCE. The weeks leading up to the 2nd Quarter financials. Silence until the minimum day requirement to post and file for a conference call. Then out of the blue sky came the Sanofi announce 12 hours before the 2nd quarter call. What happened after that call on Monday? SILENCE. Either management is very incompetent or the smarter than a fox. There is more to come. Perhaps Al almost spilled the beans on Monday. Perhaps whatever it is will not be announce for another quarter or two. Maybe it deals with a bigger plan of finality of MannKind and its agreement with Sanofi or perhaps it includes the Partnership that Sanofi announced in June with Medtronic.
Medtronic can't really make any new announcements until they finish their inversion with Covidien. I am not sure when that is to be finalized but I would assume before the end of 2014 or first quarter 2015. Maybe there will be a buyout of Mannkind with the devices / technology going to MDT and Afrezza going to Sanofi.
Where there is SILENCE there is something more happening at MannKind.
|
|
|
|
Post by bradleysbest on Aug 14, 2014 16:44:56 GMT -5
I sure hope so!
|
|
|
|
Post by cybergym66 on Aug 14, 2014 17:08:24 GMT -5
I disagree. Something is on the horizon. Going back to FDA approval. They knew the deal coming with Sanofi and did their best to keep it under wraps. Management could have hit TV and other media for weeks talking about the significance of getting FDA approval. Such a big milestone. What did we get SILENCE. The weeks leading up to the 2nd Quarter financials. Silence until the minimum day requirement to post and file for a conference call. Then out of the blue sky came the Sanofi announce 12 hours before the 2nd quarter call. What happened after that call on Monday? SILENCE. Either management is very incompetent or the smarter than a fox. There is more to come. Perhaps Al almost spilled the beans on Monday. Perhaps whatever it is will not be announce for another quarter or two. Maybe it deals with a bigger plan of finality of MannKind and its agreement with Sanofi or perhaps it includes the Partnership that Sanofi announced in June with Medtronic.
Medtronic can't really make any new announcements until they finish their inversion with Covidien. I am not sure when that is to be finalized but I would assume before the end of 2014 or first quarter 2015. Maybe there will be a buyout of Mannkind with the devices / technology going to MDT and Afrezza going to Sanofi.
Where there is SILENCE there is something more happening at MannKind.
"SILENCE!!! I'll Kill You!!!" - Achmed the Dead Terrorist |
|
|
|
Post by dreamboatcruise on Aug 14, 2014 17:12:02 GMT -5
I disagree. Something is on the horizon. Going back to FDA approval. They knew the deal coming with Sanofi and did their best to keep it under wraps. Management could have hit TV and other media for weeks talking about the significance of getting FDA approval. Such a big milestone. What did we get SILENCE. The weeks leading up to the 2nd Quarter financials. Silence until the minimum day requirement to post and file for a conference call. Then out of the blue sky came the Sanofi announce 12 hours before the 2nd quarter call. What happened after that call on Monday? SILENCE. Either management is very incompetent or the smarter than a fox. There is more to come. Perhaps Al almost spilled the beans on Monday. Perhaps whatever it is will not be announce for another quarter or two. Maybe it deals with a bigger plan of finality of MannKind and its agreement with Sanofi or perhaps it includes the Partnership that Sanofi announced in June with Medtronic.
Medtronic can't really make any new announcements until they finish their inversion with Covidien. I am not sure when that is to be finalized but I would assume before the end of 2014 or first quarter 2015. Maybe there will be a buyout of Mannkind with the devices / technology going to MDT and Afrezza going to Sanofi.
Where there is SILENCE there is something more happening at MannKind.
And maybe it's what would seem very straightforward and stated in responses to various questions... Sanofi doesn't want to give away details that would clue their competition in to their plans at this time. Little that Mannkind could say now would be meaningful other than sales projections... and from the call we know that this is info Sanofi does not presently want out. That fact does not make Mannkind management "incompetent" but it also isn't an indicator of some vast new deal lurking under the surface ready to be sprung on short traders by a crafty old billionaire. Al and company are incredibly smart and competent, but they aren't playing some game to manipulate share price. They are focusing on doing what they've indicated... bringing a game changing product to market that will have huge benefits to millions of patients. We know that the full details of this deal will be released with the next earnings call. I'm hoping that will paint the deal in a more positive light. That seems a reasonable hope. A secret deal with Medtronic seems unfounded wishful thinking. |
|
|
|
Post by daduke38 on Aug 16, 2014 6:40:45 GMT -5
I disagree. Something is on the horizon. Going back to FDA approval. They knew the deal coming with Sanofi and did their best to keep it under wraps. Management could have hit TV and other media for weeks talking about the significance of getting FDA approval. Such a big milestone. What did we get SILENCE. The weeks leading up to the 2nd Quarter financials. Silence until the minimum day requirement to post and file for a conference call. Then out of the blue sky came the Sanofi announce 12 hours before the 2nd quarter call. What happened after that call on Monday? SILENCE. Either management is very incompetent or the smarter than a fox. There is more to come. Perhaps Al almost spilled the beans on Monday. Perhaps whatever it is will not be announce for another quarter or two. Maybe it deals with a bigger plan of finality of MannKind and its agreement with Sanofi or perhaps it includes the Partnership that Sanofi announced in June with Medtronic.
Medtronic can't really make any new announcements until they finish their inversion with Covidien. I am not sure when that is to be finalized but I would assume before the end of 2014 or first quarter 2015. Maybe there will be a buyout of Mannkind with the devices / technology going to MDT and Afrezza going to Sanofi.
Where there is SILENCE there is something more happening at MannKind.
kc, I think you are spot on. Neither SNY or MNKD has had anything to say since Monday. My theory is Medtronics is somehow tied up in this deal. It was obvious in the quarterly CC that not every thing has been disclosed yet! Don't you find it strange that with the FDA approval and "partnership" MNKD has been so quiet? If I just spent the 10+ past years on a project and more money than I can comprehend, I would be screaming from the Roof tops with joy! I think they have known for months that SNY was their partner. And Matt's last comment was Partners in the plural sense. I THINK that this was a temporary set-up until MDT gets everything complete. And does anyone ever wonder why SNY issued 500 million new shares they are sitting on? Why? Just me theory, but I think within a year we are owned by SNY. I don't understand all the science (other than it works better thananything out there) and legal stuff, but I do like to think I have common sense. And common sense tells me there is way more to this than they can release yet. |
|
|
|
Post by mnholdem on Aug 16, 2014 7:58:42 GMT -5
Any Licensing Agreement involving rights to patents requires a review and approval by regulators, mandated by the Hart, Scott, Rodino Antitrust act. The waiting period is 15-30 days after filing. Although the filing is not made public, according to the act, regulators may disclose certain information at their discretion.
In other words, they can legally "leak" certain information to the benefit of others, all in the name of transparency. We all understand, of course, that this enables regulators to let others get in on the action. Potentially corrupt practice IMHO.
BTW, I also wonder if Medtronic will fit into the picture.
|
|
|
|
Post by 4Balance on Aug 16, 2014 15:00:48 GMT -5
I disagree. Something is on the horizon. Going back to FDA approval. They knew the deal coming with Sanofi and did their best to keep it under wraps. Management could have hit TV and other media for weeks talking about the significance of getting FDA approval. Such a big milestone. What did we get SILENCE. The weeks leading up to the 2nd Quarter financials. Silence until the minimum day requirement to post and file for a conference call. Then out of the blue sky came the Sanofi announce 12 hours before the 2nd quarter call. What happened after that call on Monday? SILENCE. Either management is very incompetent or the smarter than a fox. There is more to come. Perhaps Al almost spilled the beans on Monday. Perhaps whatever it is will not be announce for another quarter or two. Maybe it deals with a bigger plan of finality of MannKind and its agreement with Sanofi or perhaps it includes the Partnership that Sanofi announced in June with Medtronic.
Medtronic can't really make any new announcements until they finish their inversion with Covidien. I am not sure when that is to be finalized but I would assume before the end of 2014 or first quarter 2015. Maybe there will be a buyout of Mannkind with the devices / technology going to MDT and Afrezza going to Sanofi.
Where there is SILENCE there is something more happening at MannKind.
My bet? The principals are dead tired, and are taking a break to rest and rejuvenate. |
|
|
|
Post by kc on Aug 21, 2014 15:03:36 GMT -5
Talk about silence on both sides. SNY and MNKD. You have to wonder what is up as there is always a lot of marketing preperation and publications that both companies should be populating with information on the upcoming product release. Personally I am beginning to really think its very strange that there is no news of any kind. I know that for competitive reasons they will avoid certain things that are competitive issues like pricing and approach to marketing but no information is very odd.
|
|
|
|
Post by dreamboatcruise on Aug 21, 2014 15:28:08 GMT -5
Talk about silence on both sides. SNY and MNKD. You have to wonder what is up as there is always a lot of marketing preperation and publications that both companies should be populating with information on the upcoming product release. Personally I am beginning to really think its very strange that there is no news of any kind. I know that for competitive reasons they will avoid certain things that are competitive issues like pricing and approach to marketing but no information is very odd. We know that they have decided to not release the details of the agreements until Mannkind's Q3 earnings, so I personally would be surprised if there were any further details until at least that point. I'm no expert on drug marketing, but it also doesn't strike me ass odd that marketing plans would be concealed until closer to market release date which we now know is Q1. |
|
|
|
Post by jlaw277 on Aug 21, 2014 15:36:54 GMT -5
Does anyone know if Greenhill has ever advised any other biotech company on negotiating a drug deal (not M&A) with a pharma partner? Do biotech companies usually engage an investment banker to negotiate these? Greenhill was started as a boutique M&A shop by Bobby Greenhill out of (I believe) Morgan Stanley. If you look at their transaction list ( link) this is the first deal of this type they have done going back to 2006. The deals they list are, as you would expect, either sales or acquisitions, but not deals of the SNY/MNKD sort. Makes you wonder why MNKD would contract with an investment bank who has no demonstrated expertise in this particular area. However, if you were looking for a banker for a very complex M&A transaction, Greenhill would be a great choice. Step One: Quantify and value the primary asset of the company by partnering with the best strategic entity possible. Afrezza deal terms are now set. Step Two: Having, to some degree, quantified a primary company asset, sell the participation rights to that asset and delivery technology to a suitable buyer. By partnering first, Al secures the future of what could be his final and maybe biggest contribution to the world. However, now that Afrezza is approved and in the hands of Sanofi, does Mannkind still seem like a traditional Al Mann investment? Technosphere still offers much potential and there are the cancer therapies, but both will take a lot of time and cash to be fully realized. Medtronic and Sanofi signed what a memo of understanding ( link) in mid-June. The financial terms of the deal were not disclosed. The nature of the collaboration does sound a lot like the benefits to be delivered via Afrezza. Now you have a deal between MNKD and Sanofi where deal terms seem vague and confusing at best, especially centering around how the product will be marketed. Fun to speculate. Of course, they may have used Greenhill so that in the event of a CRL, rejection or lack of partner, they would be prepped to sell the company. Or Dreamboatcruise's sensible take could also be true. We shall see. |
|
|
|
Post by kc on Aug 21, 2014 15:57:35 GMT -5
My view is still there is more to come. My speculation is that the piece with Medtronic is not finalized until after the Transaction between MDT and Covidien (COV) is consumated in the 4th qtr of 2014 or the 1st qtr of 2015. The partnership or alliance between SNY and MDT was announced the day before the announcement of the purchase of Covidien by Medtronic. To me that is strange that timing was that specific. Now they purchase needs to receive approval of a lot of different countries and the US Justice department as it involves an Tax Inversion on that transaction. So my idea is that MDT can't buy the other piece (Technosphere) until after their deal is complete and they become Covidien. Am I right or wrong? I guess only time will tell. Medtronic and Sanofi signed what a memo of understanding ( link) in mid-June. The financial terms of the deal were not disclosed. The nature of the collaboration does sound a lot like the benefits to be delivered via Afrezza. Now you have a deal between MNKD and Sanofi where deal terms seem vague and confusing at best, especially centering around how the product will be marketed. Fun to speculate. |
|
|
|
Post by daduke38 on Aug 21, 2014 16:08:18 GMT -5
Talk about silence on both sides. SNY and MNKD. You have to wonder what is up as there is always a lot of marketing preperation and publications that both companies should be populating with information on the upcoming product release. Personally I am beginning to really think its very strange that there is no news of any kind. I know that for competitive reasons they will avoid certain things that are competitive issues like pricing and approach to marketing but no information is very odd. We know that they have decided to not release the details of the agreements until Mannkind's Q3 earnings, so I personally would be surprised if there were any further details until at least that point. I'm no expert on drug marketing, but it also doesn't strike me ass odd that marketing plans would be concealed until closer to market release date which we now know is Q1. If they wait until early November it might be scary how low our PPS could go. I have to agree with KC, there is still something major to come. And I really believe MDT is the missing link to this. |
|
|
|
Post by kc on Aug 21, 2014 17:01:24 GMT -5
Here is my exact comment on this topic back in July when Psycho Analyst wrote this piece for Seeking Alpha. seekingalpha.com/article/2313645-mannkind-are-these-top-big-pharma-companies-potential-partners?source=email_rt_article_readmore&app=1&uprof=25My comment below: Psycho another good piece on Mannkind. I think your spot on in regard to Sanofi and they would make a great partner or Buy out for Mannkind. If you go back to mid June there was a big announce by Sanofi and Medtronic in forming an alliance. Could this have been for Sanofi to market Afrezza and for Medtronic to handle the device side with the Technosphere device? One has to think that it would make a great marriage to bring MannKind into the deal with the two great leaders in the market place. There is a comfort level between Alfred Mann and Medtronics and they know he is also still working on his Pancreas pump deviece. So buying in a joint venture Mannkind makes logical sense for the new alliance. One last point is that Medtronic is set to become an Irish company through the Inversion process with Covidien. Since that merger is in process it would make a lot of sense why the partnership or buyout with Mannkind has not been announced as it takes time to work out the details and contracts involved with a mega merger JUNE 15,2014 (Medtronic / Covidien) newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle_Print&ID=1939883& Attached is the press release from June 14, 2014 on the Sanofi/Medtronic deal. newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle_Print&ID=1939865&Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes So is there more to come? Perhaps 4th Quarter or 1st Quarter 2015.
|
|
